Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells

PURPOSE: The Phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclit...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Morgillo, Floriana, Della Corte, Carminia Maria, Diana, Anna, Mauro, Concetta di, Ciaramella, Vincenza, Barra, Giusi, Belli, Valentina, Franzese, Elisena, Bianco, Roberto, Maiello, Evaristo, de Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2017
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652721/
https://ncbi.nlm.nih.gov/pubmed/29100327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20385
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items